I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 26 studies | 24% ± 7% | |
| CD8-positive, alpha-beta T cell | 14 studies | 24% ± 7% | |
| CD16-positive, CD56-dim natural killer cell, human | 13 studies | 30% ± 9% | |
| mast cell | 12 studies | 25% ± 8% | |
| mature NK T cell | 12 studies | 24% ± 8% | |
| gamma-delta T cell | 12 studies | 25% ± 5% | |
| CD16-negative, CD56-bright natural killer cell, human | 11 studies | 26% ± 7% | |
| CD8-positive, alpha-beta memory T cell | 9 studies | 24% ± 5% | |
| mucosal invariant T cell | 7 studies | 24% ± 4% | |
| effector memory CD8-positive, alpha-beta T cell | 5 studies | 23% ± 6% | |
| exhausted T cell | 4 studies | 21% ± 6% | |
| epithelial cell | 4 studies | 23% ± 8% | |
| CD4-positive, alpha-beta T cell | 4 studies | 19% ± 2% | |
| naive thymus-derived CD8-positive, alpha-beta T cell | 4 studies | 22% ± 7% | |
| T cell | 3 studies | 17% ± 2% | |
| effector CD8-positive, alpha-beta T cell | 3 studies | 21% ± 5% | |
| group 3 innate lymphoid cell | 3 studies | 26% ± 4% | |
| innate lymphoid cell | 3 studies | 24% ± 5% | |
| plasmacytoid dendritic cell | 3 studies | 28% ± 4% |
